Mylenda Injection 0.5 mg/0.5 ml contains Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used for the effective management of type 2 diabetes mellitus. This strength is commonly prescribed as a maintenance dose following initial dose titration and is intended to provide sustained glycemic control in adult patients when lifestyle modification alone is insufficient.

Semaglutide mimics the action of endogenous GLP-1, a hormone involved in glucose regulation. It enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses excessive glucagon release, and slows gastric emptying. These mechanisms work together to reduce both fasting and postprandial blood glucose levels. In addition, semaglutide influences appetite regulation in the central nervous system, which often results in reduced caloric intake and gradual weight loss—an important benefit for many patients with type 2 diabetes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Mylenda Injection 0.5 mg is indicated as an adjunct to diet and exercise for:

• Treatment of type 2 diabetes mellitus in adults

• Patients requiring improved glycemic control after initial dose escalation

• Use as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, or insulin, as advised by a physician

Dosage and Administration

Mylenda Injection is administered via subcutaneous injection. The 0.5 mg dose is typically initiated after patients have tolerated the lower starting dose. It is administered once weekly, on the same day each week, at any time of the day, with or without meals.

The injection may be given in the abdomen, thigh, or upper arm. Injection sites should be rotated to minimize local reactions. Dosage adjustments should be made under medical supervision based on glycemic response and tolerability.

Key Benefits

• Effective and sustained blood glucose reduction

• Convenient once-weekly dosing regimen

• Low risk of hypoglycemia when not used with insulin or sulfonylureas

• Supports weight reduction alongside glycemic control

• Well-established efficacy and safety profile

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis

• Use with caution in patients with a history of pancreatitis

• Contraindicated in patients with a personal or family history of medullary thyroid carcinoma

• Gastrointestinal adverse effects are more common during dose escalation

• Regular monitoring of blood glucose is recommended

Adverse Effects

Common adverse reactions associated with semaglutide include:

• Nausea and vomiting

• Diarrhea or constipation

• Abdominal pain or discomfort

• Decreased appetite

• Mild injection site reactions

These effects are generally transient and decrease with continued treatment.

Storage Conditions

Store Mylenda Injection in a refrigerator at 2°C–8°C. Do not freeze. Protect from light. Follow manufacturer instructions regarding storage after first use. Keep out of reach of children.

Conclusion

Mylenda Injection 0.5 mg/0.5 ml (Semaglutide) offers an effective and convenient once-weekly injectable option for the long-term management of type 2 diabetes mellitus. By providing reliable glycemic control along with potential weight reduction, it supports comprehensive diabetes care when used under appropriate medical guidance.